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The signal pathways and treatment of cytokine storm in
COVID-19
Lan Yang1,2, Xueru Xie1,2, Zikun Tu1,2, Jinrong Fu 3, Damo Xu4,5 and Yufeng Zhou 1,2
The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis and is more devastating than any other previous
infectious disease. It has affected a significant proportion of the global population both physically and mentally, and destroyed
businesses and societies. Current evidence suggested that immunopathology may be responsible for COVID-19 pathogenesis,
including lymphopenia, neutrophilia, dysregulation of monocytes and macrophages, reduced or delayed type I interferon (IFN-I)
response, antibody-dependent enhancement, and especially, cytokine storm (CS). The CS is characterized by hyperproduction of an
array of pro-inflammatory cytokines and is closely associated with poor prognosis. These excessively secreted pro-inflammatory
cytokines initiate different inflammatory signaling pathways via their receptors on immune and tissue cells, resulting in complicated
medical symptoms including fever, capillary leak syndrome, disseminated intravascular coagulation, acute respiratory distress
syndrome, and multiorgan failure, ultimately leading to death in the most severe cases. Therefore, it is clinically important to
understand the initiation and signaling pathways of CS to develop more effective treatment strategies for COVID-19. Herein, we
discuss the latest developments in the immunopathological characteristics of COVID-19 and focus on CS including the current
research status of the different cytokines involved. We also discuss the induction, function, downstream signaling, and existing and
potential interventions for targeting these cytokines or related signal pathways. We believe that a comprehensive understanding of
CS in COVID-19 will help to develop better strategies to effectively control immunopathology in this disease and other infectious
and inflammatory diseases.
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INTRODUCTION
Coronavirus Disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread
worldwide and was declared a pandemic in early 2020. COVID-19
destroyed people’s mental and physical health and staggered
global economic growth. As of May 18, 2021, 163 million
infections, including 3.38 million deaths, have been recorded
(source: World Health Organization). SARS-CoV-2 invades the host
by virtue of angiotensin-converting enzyme 2 (ACE2) receptors
broadly distributed on various tissues and immune cells.1–5 The
virus can cause a wide range of clinical manifestations from mild
forms such as fever, cough, and myalgia to moderate forms
requiring hospitalization (pneumonia and localized inflammation)
to severe/critical forms with fatal outcomes.6,7 Severe or critical
infection often manifests as pneumonia,8,9 disseminated intravas-
cular coagulation (DIC), acute respiratory distress syndrome
(ARDS), low blood pressure, and multiorgan failure (Fig. 1).9–11
Several lines of evidence have shown that immunopathological
damage may be responsible for the deterioration of COVID-19.
Particularly, multiple studies have reported that highly elevated
levels of pro-inflammatory cytokines are produced during the
crosstalk between epithelial cells and immune cells in COVID-19,
which has linked the cytokine storm (CS) with the severe
complications and poor outcomes in this infection.12–14
CS is a fast-developing, life-threatening, clinical condition in
which the overproduction of inflammatory cytokines and exces-
sive activation of immune cells lead to complicated medical
syndromes from a persistent fever, nonspecific muscle pain, and
hypotension, to capillary leak syndrome, DIC, ARDS, hemophago-
cytic lymphohistiocytosis (HLH), multiorgan failure, and death if
treatment is not adequate.15 Therefore, the timing of diagnosis
and treatment of CS could be life-saving. The term CS was first
used in 1993 in graft-versus-host disease,16 and later, in many
inflammatory diseases such as autoimmune conditions, organ
transplantation, cancer chimeric antigen receptor (CAR) T cell
therapy, and, most recently, in COVID-19.17–23 However, the profile
and causative effect of CS in different conditions can greatly vary.
Thus far, precise diagnosis and treatment guidelines for CS in most
of the conditions are lacking. Understanding the definite
alterations and pathogenic roles of individual cytokines involved
in the COVID-19-related CS (COVID-CS) is hence extremely
important for the development of precise diagnosis and effective
treatment.
Although some aspects of this topic have been partly reviewed
previously, a comprehensive view of COVID-CS to facilitate its
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diagnosis and treatment is still lacking with unmet clinical needs.
Herein, we provide an updated and full scenario of COVID-CS from
basic research to clinical diagnosis, treatment, and trials. Initially,
we discuss the currently identified immunopathological features
of COVID-19, especially the CS; its mechanism of action and
differences with respect to CS in other disease conditions; and
individual cytokines involved in the COVID-CS including their
pathological role, downstream signaling, and existing interven-
tions. In addition, the challenges and prospects in the diagnosis
and treatment of COVID-CS are also discussed.
THE IMMUNOPATHOLOGY OF COVID-19
In general, patients with COVID-19 present with an abnormal
immune landscape, characterized by overactivated inflammatory,
innate immune response, and impaired protective, adaptive
immune response. This is primarily responsible for the immuno-
pathology of severe COVID-19. Thus far, evidence from both
clinical trials and basic research has revealed several key features
of immunopathology in severe COVID-19, including lymphopenia,
antibody-dependent enhancement (ADE), neutrophilia, dysregula-
tion of monocytes and macrophages, reduced or delayed type I
interferon (IFN-I) response, and CS (Fig. 2).
Lymphopenia
Lymphopenia was commonly found in COVID-19 patients10,11
and is closely correlated with the illness severity.24,25 Laboratory
results showed that the counts and percentages of lymphocytes
including CD4+ T, CD8+ cytotoxic T,26,27 natural killer (NK),24 and
B cells25 were all reduced in COVID-19 patients.28–31 Evidence
from single-cell sequencing,32 flow cytometry,33 and nonhuman
primate models of COVID-1934 confirmed the involvement of
lymphopenia to the maximum extent. In addition, T cells
exhibited exhaustion phenotypes with the expression of higher
levels of exhaustion markers including programmed cell death
protein-1 (PD-1) and T cell immunoglobulin and mucin domain-
3, suggesting that these T cells may have regulatory
activities.26,27 Other investigations showed that the PD-1- or
NK group 2 member A-positive NK cells were also significantly
increased in the peripheral blood of COVID-19 patients
compared to healthy controls.35,36
Several mechanisms may contribute to SARS-CoV-2-induced
depletion and exhaustion of lymphocytes: (1) SARS-CoV-2 may
directly infect T cells via ACE2 receptor expressed on T cells,37
which results in T cell death;38,39 (2) several pro-inflammatory or
anti-inflammatory cytokines can accelerate the depletion and
exhaustion of T cells with their respective functions. In addition,
the virus may destroy secondary lymphoid tissues spleen and
lymph nodes, leading to lymphopenia, which is supported by the
observations of splenic atrophy, lymph node necrosis, and
decreased lymphocyte numbers;24,40–42 (3) a nonhuman primate
COVID-19 model showed that the impaired anti-viral T cell
response may be attributed to the increased numbers of
regulatory T cells (Tregs).34 However, we cannot exclude the
possibility that depletion and exhaustion of lymphocytes resulted
from anti-inflammatory therapies such as the administration of
glucocorticoids.
Collectively, lymphopenia may represent a poor outcome of the
illness. A retrospective, multicenter, emergency clinical trial in a
Han Chinese population including 14,117 normal controls and 69
hospitalized COVID-19 patients (25 severe or critical and 44 mild)
showed that lymphopenia occurred in almost 100% of the severe/
critical cases, and the number of lymphocytes progressively
decreased with the progression of the disease and deterioration of
clinical status. The CD4+ and CD8+ T lymphocyte subsets showed
a marked difference between mild and severe cases. Therefore,
the authors suggested that analyzing the counts and percentages
of lymphocytes at admission immediately contributes to improved
clinical prognosis.43
Antibody-dependent enhancement
B cells are considered protective in SARS-CoV-2 infection by
producing neutralizing antibodies against the ACE2 receptor to
prevent viral entry.44 However, B cell-produced neutralizing
antibodies are not necessarily protective, depending on the
virus element it targets and also the Fc region of the antibody.
ADE is a phenomenon wherein pre-existing neutralizing anti-
bodies targeting one serotype of a given virus enhance the
entry of not only that virus but also another serotype of the virus
into leukocytes through the interaction between the Fc regions
of the antibody and Fc receptors or complement receptors on
such cells.45–49 The ADE phenomenon has been found in various
viral infections such as dengue, Flavivirus, SARS-CoV, MERS-CoV,
and Ebola.45,48,50–52
Recent studies have shown that relatively high levels of B cells
or antibodies are positively associated with COVID-19 sever-
ity,32,53,54 implying the potential involvement of ADE in SARS-CoV-
2 infection. In addition, a study has reported that the monoclonal
antibody MW05 targeting SARS-CoV-2 may also induce ADE
activity by binding to FcγRIIB receptors on the target cells in vitro.
However, administration of an engineered antibody with Fc region
mutation in vivo effectively protected animals from SARS-CoV-2
infection.55 This highlights the importance of developing protec-
tive neutralizing antibodies against SARS-CoV-2. Nevertheless,
further investigations about ADE in SARS-CoV-2 infection are
required to facilitate the development of vaccine- or antibody-
based therapy for COVID-19.
Neutrophilia
An increase in neutrophil count in COVID-19 patients is widely
recognized. It is well known that under normal conditions,
neutrophils play a protective role against infections by producing
neutrophil extracellular traps (NETs) to kill extracellular patho-
gens;56 however, excessive neutrophil activation can also damage
the surrounding cells and dissolve connective tissues.57
Fig. 1 A systemic clinical manifestations of COVID-19. SARS-CoV-2
infects airway epithelial cells or immune cells via binding to ACE2
receptors, causing tissue damage and release of DAMPs, as well as
production of inflammatory cytokines by epithelial cells and
immune cells. Then, the crosstalk between epithelial cells and
immune cells leads to a wide range of clinical manifestations, from
mild forms (e.g., fever, cough, and myalgia); to moderate forms
requiring hospitalization (pneumonia and localized inflammation);
to severe/critical forms with a fatal outcome that are manifested as
pneumonia, ARDS, DIC, CS, and multiorgan failure. DAMP danger-
associated molecular pattern, ARDS acute respiratory distress
syndrome, DIC disseminated intravascular coagulation
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An earlier clinical trial including 138 patients from Wuhan,
China, showed that neutrophil counts were increased in non-
survivors compared to survivors and continued to increase until
death in the non-survivors.11 Another clinical study that integrated
transcriptomic, proteomic, and metabolomic platforms showed
that neutrophil counts were increased in patients with severe, but
not mild, COVID-19 as compared to healthy controls, and
molecules associated with NETs were significantly upregulated
in severe COVID-19 cases.58
The increased neutrophils manifested as both increased
numbers of mature and immature cells. In a clinical trial that
integrated single-cell RNA-sequencing with single-cell proteomics
of blood and peripheral blood mononuclear cells (PBMCs),
immature neutrophil precursors, and dysfunctional mature
neutrophils expressing programmed death-ligand 1 appeared in
severe COVID-19 cases.59 In addition, a single-cell sequencing
analysis by Wilk et al.32 and a flow cytometry analysis by Ronit
et al.33 also identified the appearance of neutrophil progenitors at
various developmental stages in PBMCs or bronchoalveolar lavage
fluid (BALF) of COVID-19 patients with ARDS.
Although the mechanism by which the virus promotes
neutrophil development in COVID-19 is still poorly understood,
McElvaney et al.60 found that the levels of pyruvate kinase M2
(PKM2), a regulator of glycolysis61 and coactivator of hypoxia-
inducible factor-1α,62 as well as phosphorylated PKM2 were higher
in the neutrophils of COVID-19 patients in the ICU than in those of
non-ICU COVID-19 patients. This indicates that neutrophils
undergo immunometabolic reprogramming in severe COVID-19
cases, which represents a potential intervention target for
excessive neutrophil generation and activation in severe or critical
COVID-19.
Dysregulation of monocytes and macrophages
Monocytes and macrophages are the major innate immune cells
in infection and inflammation not just by virtue of their higher
numbers but also by their functions. A single-cell RNA-sequencing
analysis showed that classic CD14+ monocytes were significantly
increased, whereas nonclassical CD16+ monocytes and inter-
mediate CD14+CD16+ monocytes were remarkably reduced in the
blood of COVID-19 patients with severe symptoms. Classical
monocytes can differentiate into macrophages in tissue to initiate
an inflammatory response, whereas nonclassical monocytes were
viewed as anti-inflammatory as they can maintain vascular
homeostasis,63 which may explain the phenotypic shift of
circulating monocytes from CD16+ to CD14+. Analysis of the
differentiation profiles of BALF and circulating
monocyte–macrophages from the same patient revealed a
transition course of blood-toward-BALF. More importantly, multi-
ple pro-inflammatory cytokines and chemokines were highly
expressed by the BALF monocyte–macrophages, suggesting that
the cells are inflamed.64 Another single-cell sequencing analysis of
peripheral blood samples also showed that CD16+ monocytes
were remarkably depleted in COVID-19 patients with ARDS, with a
phenotypic shift from CD16+ to CD14+. However, significant
upregulation of genes encoding pro-inflammatory cytokines or
chemokines were not found in peripheral monocytes, indicating
that peripheral monocytes may not be responsible for the
progression of CS in COVID-19.32 Moreover, phenotyping leuko-
cyte subpopulations in BALF and blood of COVID-19 patients with
ARDS showed that the expression of activation markers such as
CD16, CD64, CD69, and HLA-DR was higher in BALF macrophages
than in peripheral macrophages.33 Collectively, these existing
studies were generally consistent and revealed the course of
Fig. 2 The key immunopathology of severe COVID-19. The immunopathological manifestations of COVID-19 include lymphopenia,
dysregulation of monocytes and macrophages, neutrophilia, ADE, reduced or delayed IFN-I response, and CS. Lymphopenia is commonly
observed in severe COVID-19. In addition to decreased counts, lymphocytes often exhibit exhaustion phenotypes with the expression of
higher levels of exhaustion markers PD-1, Tim-3, or NKG2A. Peripheral monocytes present a phenotype shift from CD16+ to CD14+, and BALF
macrophages are increased with a blood-to-BALF transition course. Neutrophil counts are increased with the presence of neutrophil
precursors in peripheral blood, especially in patients with severe COVID-19. The possible existence of ADE enhances the entry of SARS-CoV-2
into cells through interaction between Fc regions and Fc receptors, leading to the aggravation of COVID-19. A CS is characterized by highly
elevated levels of pro-inflammatory mediators and is a particularly central feature for poor outcomes in patients with severe or critical
infection. Reduced or delayed IFN-I response impedes viral clearance and induces paradoxical hyperinflammation, thus leading to the
deterioration of prognosis in COVID-19 patients. BALF bronchoalveolar lavage fluid, ADE antibody-dependent enhancement
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blood-toward-BALF transition and the contribution of pulmonary
monocyte–macrophages to CS via the release of multiple pro-
inflammatory cytokines and chemokines during severe COVID-19.
Interestingly, a two-cohort study showed that activated HLA-
DRhighCD11chighCD14+ monocytes were increased in the PBMCs of
patients with mild COVID-19, whereas dysfunctional HLA-
DRlowCD163high (indicative of anti-inflammatory function) CD14+
monocytes were observed in severe COVID-19 cases.59 This merits
further investigation to understand the underlying mechanism
and clinical significance.
Reduced or delayed IFN-I response
The IFN-I response is the first line of protective response and
critical to combat viral infections by promoting viral clearance and
regulating innate and adaptive immune responses.65 Although the
detailed mechanism is still unknown when the infection occurs,
the RNA of SARS-CoV-2 virus may be recognized by innate
immune cells via pattern recognition receptors (PRRs) including
toll-like receptor (TLR); retinoic acid-inducible gene-I (RIG-I)-like
receptors (RLRs)/melanoma differentiation-associated gene 5
(MDA5); and NOD-like receptors (NLRs).66 Subsequently, down-
stream transcription factors including nuclear factor-κB (NF-κB),
activator protein-1 (AP-1), and IFN regulatory factor 3/7 (IRF3/7)
are activated to promote the transcription of pro-inflammatory
cytokines and IFN-I. The IFN-I can activate the Janus kinase 1
(JAK1)/tyrosine kinase 2–signal transducer and activator of
transcription 1/2 (STAT1/2) pathway, promoting the formation of
the STAT1/2/IRF9 complex and initiating transcription of IFN-
stimulated genes (ISGs) (Fig. 3).66,67
However, accumulating evidence has suggested that the
protective IFN-I response was remarkably reduced in severe
COVID-19 patients.26,68,69 At least two mechanisms have been
proposed to explain the deficient IFN-I response: (1) previous
studies have suggested that SARS-CoV employs various mechan-
isms to inhibit IFN response, especially through the components
of its structural proteins such as M protein,70 N protein,71 open-
reading frame 3a (ORF3a) protein,72 and ORF6 protein.73
Considering that the structure of SARS-CoV-2 is similar to that of
SARS-CoV, it can be speculated that SARS-CoV-2 may exert similar
effects on IFN response. For example, Yang et al.74 found that the
NSP1 protein of SARS-CoV-2 can inhibit STAT1 phosphorylation
and ISG transcription. (2) Decreased plasmacytoid dendritic cells
(pDCs) may be partly responsible for the deficient IFN-I response.
Sufficient evidence has suggested that pDC is a prominent
producer of IFN-I upon viral infection.75–77 However, existing
studies showed that counts of pDCs were decreased in the blood
of COVID-19 patients, especially in severe cases.26,32
Of note, although the levels of systemic IFN-I were low, local
IFN-I and ISGs were noticeable in the BALF of some critically ill
patients,78 which are related to the phenomenon of delayed IFN-I
response.69 Evidence has confirmed that a delayed IFN-I response
not only impedes viral clearance but also induces paradoxical
hyperinflammation, thereby aggravating the immunopathological
response.79,80 Collectively, these studies suggest that IFN-I-based
therapy for COVID-19 should be applied as early as possible after
the infection is confirmed.
Cytokine storm
In this section, we systemically review and discuss the character-
istics, possible induction mechanism, pathogenesis, and diagnosis
of CS in COVID-19.
Sufficient evidence has revealed the components and character-
istics of CS in the patients with severe COVID-19, which are
composed of an array of cytokines including interleukin-1 (IL-1), 2, 6,
Fig. 3 The signaling pathways for the production and function of IFN-I after SARS-CoV-2 infection. After infection, the genomic ssRNAs and
replicative dsRNA intermediates of SARS-CoV-2 are recognized by endosomal toll-like receptors TLR3, 7, 8, and cytosolic RNA sensors, RIG-1/
MDA5; next, downstream transcription factors including NF-κB and IRF3/7 are activated to induce the production of pro-inflammatory
cytokines and IFN-I. IFN-I can activate the JAK1/TYK2–STAT1/2 pathway, promoting the formation of the STAT1/2/IRF9 complex and initiating
the transcription of ISGs to produce anti-virus mediators, and it can also nonconventionally activate inflammatory pathways such as NF-κB
and MAPK pathways to induce the expression of pro-inflammatory cytokines and paradoxical hyperinflammation in COVID-19
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7, 8, 10, 12, 17, 18; tumor necrosis factor-α (TNF-α); IFN-γ; granulocyte
colony-stimulating factor (G-CSF); granulocyte–macrophage colony-
stimulating factor (GM-CSF); and monocyte chemoattractant
protein-1 (MCP-1).26,33,60,81–86 Reports of hemophagocytosis and
clinical benefits from cytokine-targeted therapies in severe COVID-
19 patients further confirmed the existence and pathogenesis of
COVID-CS.87,88 Existing evidence has characterized and distinguished
COVID-CS from CS in variable conditions such as HLH induced by
specific viral infections,89 macrophage activation syndrome (MAS)
occurring after autoimmune disorders,90 and cytokine release
syndrome (CRS) caused by CAR T cell therapy23 in several aspects.
First, COVID-CS involves more inflammatory cytokines than other CS
conditions, thereby providing an explanation for the aggressive
nature of COVID-19. Second, lymphopenia, although relatively less
frequent in other CS, was often observed in patients with COVID-
CS,88 suggesting that COVID-CS may be mainly attributed to innate
—rather than adaptive immune cells. Finally, compared with
bacterial infection-induced CS (e.g., sepsis), the treatment of
COVID-CS is more challenging, because blocking inflammatory
cytokine function without effective anti-viral drug support may
exacerbate the infection.
The initiation of COVID-CS induction during infection and the
predominant causative cytokine in COVID-19 immunopathology
remain largely unknown. Despite the lack of definite pathogen-
associated molecule pattern (PAMP) of SARS-CoV-2, in analogy
with SARS-CoV and MERS-CoV, it can be speculated that upon
cellular entry of SARS-CoV-2 via its ACE2 receptor, viral genomic
single-stranded RNA or other RNA compositions (double-stranded
RNA) as PAMPs can be sensed by the related PRRs, including TLRs
and RLRs in host cells. The downstream transcription factors IRF3/
7 and NF-κB are activated following PAMP recognition to induce
the production of IFN-I and pro-inflammatory cytokines, respec-
tively.91–93 However, as mentioned above, the protective IFN-I
response is quickly and selectively abrogated by SARS-CoV-2 via
different mechanisms. This is accompanied by an overwhelming
production of pro-inflammatory cytokines in the context of
COVID-19, which not only impairs viral clearance but also
promotes paradoxical hyperinflammation including CS. Therefore,
from the immunology perspective, COVID-CS may be an
unfortunate event whereby the intended host immune response
combating the SARS-CoV-2 has lost control and transformed into
an inflammatory type.15
In SARS-CoV-2 infection, the virus infects the respiratory
epithelial tissue and activates local innate immune cells to release
inflammatory cytokines such as IL-1, IL-6, IL-8, IL-12, TNF-α, and
other chemokines. These inflammatory cytokines and chemokines
then recruit more innate immune cells (monocytes, macrophages,
neutrophils, DCs, and NK cells) and activate adaptive immune cells
(CD4+ and CD8+ T cells) from the peripheral tissues to produce
sustained inflammatory cytokines like IL-2, IFN-γ, and TNF-α, which
induce myelopoiesis and emergency granulopoiesis that further
aggravate lung and epithelial damage (Fig. 4). In addition,
overproduction of systemic cytokines, particularly IL-2, IFN-γ,
GM-CSF, and TNF-α, triggers macrophage activation (i.e., MAS) and
erythro-phagocytosis (i.e., HLH), resulting in anemia,94,95 as well as
causes perturbation of coagulation and vascular hemostasis,
resulting in capillary leak syndrome, thrombosis,96 and DIC. These
events together lead to ARDS, multiorgan failure, and death (Fig.
4).15 Of note, the host immunoregulatory system is usually capable
of retaining and fine-tuning the protective inflammation to an
appropriate level. Regulatory cells such as Tregs97,98 can produce
regulatory cytokines like IL-10 and tumor growth factor-β to
antagonize overactivated immune responses.99,100 However,
aggressive inflammatory conditions such as CS cannot be calmed
by the regulatory system’s natural ability.
Although the immunological and pathological understanding of
COVID-CS has provided valuable information regarding the
development of diagnosis and treatment strategies, detailed
Fig. 4 The immunopathological mechanisms of COVID-CS. SARS-CoV-2 infects the epithelial cells or immune cells, causing tissue damage and
release of inflammatory cytokines (e.g., IL-1, IL-6, IL-12, and TNFα) by epithelial cells and immune cells. These inflammatory cytokines then
recruit innate immune cells (monocytes, macrophages, neutrophils, DCs, and NK cells) and activate adaptive immune cells (CD4+ T cells and
CD8+ T cells) to induce the occurrence of myelopoiesis and emergency granulopoiesis, as well as the production of sustained and excessive
circulating cytokines that can further aggravate epithelial damage. In addition, overproduction of systemic cytokines triggers macrophage
activation (i.e., MAS) and erythro-phagocytosis (i.e., HLH), resulting in anemia and gives rise to perturbation of vascular hemostasis, resulting in
capillary leak syndrome, thrombosis, and DIC. These events together lead to ARDS, multiorgan failure, and death. HLH hemophagocytic
lymphohistiocytosis, MAS macrophage activation syndrome, ARDS acute respiratory distress syndrome, DIC disseminated intravascular
coagulation
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guidelines are still lacking. Developing scoring systems such as
HScore, MS score, HLH-2004, Penn grading scale, and the
Common Terminology Criteria for Adverse Events may be
beneficial to predict COVID-CS or related outcomes. Caricchio
et al.101 proposed predictive criteria for COVID-CS diagnosis. These
criteria comprise three clusters: (1) albumin <2.87 mg/mL,
lymphocytes <10.2%, neutrophil absolute count >11.4 × 103/mL;
(2) alanine aminotransferase >60 IU/L, aspartate aminotransferase
>87 IU/L, D-dimer >4930 ng/mL, lactate dehydrogenase >416 U/L,
troponin I >1.09 ng/mL; and (3) anion gap <6.8 mmol/L, chloride
>106mmol/L, potassium >4.9 mmol/L, and blood urea nitrogen:
creatinine ratio >29. In addition, ferritin >250 ng/mL and C-
reactive protein (CRP) >4.6 mg/dL are added for the reassurance of
ongoing systemic inflammation. In another study, the authors
proposed that a diagnostic criterion including peripheral blood
oxygen saturation to the fraction of inspired oxygen (SpO2/FiO2),
CRP, ferritin, cytokines/chemokines, and neutrophil/lymphocyte
ratio may have a strong diagnostic power for COVID-CS.102 Mehta
et al.13 proposed that prospective screening for hyperinflamma-
tion using laboratory assays and the HScore should be performed
in all severely ill COVID-19 patients to identify COVID-CS. Despite
the requirement for further validation, these criteria indeed
provide constructive suggestions for the development of officially
recognized guidelines for COVID-CS.
COVID-CS is a complicated and dynamic inflammatory process
caused by a group of cytokines from initiation, immune cell
hyperactivation, to organ dysfunction. The development of
precise therapeutic intervention in appropriate time is required
to effectively control COVID-CS. In principle, the treatment
strategy is to control ongoing inflammatory response by
specifically or nonspecifically targeting inflammatory cytokines
or related signaling pathways and to resume the host
immunoregulatory system. Herein, we discuss the role of the
key cytokines and associated signal pathways involved in
COVID-CS (Fig. 5).
IL-6/JAK/STAT signaling. A retrospective, multicenter study
including 150 patients from Wuhan, China showed significantly
elevated levels of IL-6 in severe COVID-19 cases.103 A study from
Germany showed that IL-6 >80 pg/mL in combination with CRP
>97mg/L presented a relatively high specificity and sensitivity to
predict respiratory failure.104 In addition, other studies have also
shown the remarkably increased serum levels of IL-6 in patients
with severe COVID-19.68,105,106
IL-6, first produced by monocytes, macrophages, and DCs,
serves as a prominent activator of the JAK/STAT3 pathway in the
context of inflammation. Recent studies have determined that the
IL-6–JAK–STAT3 axis is closely related to the severity of COVID-
19,107,108 and the levels of phosphorylated STAT3 were higher in
different subsets of leukocytes in COVID-19 patients than in
healthy controls.109 IL-6 deploys two signaling pathways—classic
cis-signaling and trans-signaling—to trigger the activation of
downstream JAK/STAT3 signaling through the membrane-bound
(mIL-6R) and soluble form of IL-6R (sIL-6R), respectively.110 In cis-
signaling, IL-6 binds to mIL-6Rs that are restrictedly expressed on
immune cells, forming an IL-6/IL-6R/gp130 complex to activate
downstream JAK/STAT3, Akt/mTOR, and MAPK signaling. This
exerts pleiotropic effects on immune cells, which are manifested
as promoted differentiation of T-helper type 17 (Th17), CD8+ T,
and B cells; increased migration of neutrophils; and reduced
development of Tregs.111,112 These, in turn, induce increased
secretion of IL-6 and aggravate inflammation. In trans-signaling,
circulating IL-6 binds to sIL-6Rs to form a complex, then binds with
the gp130 dimer that is expressed on almost all cell types. The
resultant activation of the JAK–STAT3 signaling occurs in cells with
absent expression of mIL-6R, such as endothelial cells and vascular
smooth muscle cells (VSMCs). The overwhelming activation of the
IL-6–IL-6R–JAK–STAT3 pathway triggers the secretion of various
mediators, such as IL-6 itself, IL-8, MCP-1, and vascular endothelial
growth factor (VEGF), and reduces the expression of E-cadherin
expressed on endothelial cells.113 Several studies have shown that
Fig. 5 Inflammatory signaling cascades activated in COVID-CS. SARS-CoV-2 enters the host cells and is sensed by toll-like receptors (TLRs)3, 7,
8; RIG-I-like receptor, RIG-I or MDA5; and NOD-like receptor, NLRP3, that can also be directly activated by viral proteins or ROS released by
apoptotic or inflamed cells. The downstream transcription factors IRF3/7 are activated to induce the production of IFN-I and related
paradoxical hyperinflammation; NF-κB is activated to induce the production of pro-inflammatory cytokines; and NLRP3 inflammasome is
activated to induce the production of mature IL-1β and IL-18. Pro-inflammatory cytokines such as IL-6, IL-2, TNF-α, and IFN-γ in turn activate
the JAK-STAT or NF-κB signaling via binding to their receptors expressed on immune cells to induce more production of pro-inflammatory
genes, forming a positive feedback to trigger the threshold of CS. Conversely, regulatory cytokines like IL-10 are compensatorily produced to
antagonize immune hyperactivity
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MCP-1 can facilitate the formation of atherogenesis,114 production
of adhesion molecules,115,116 and proliferation and migration of
VSMCs,117 which partly explains the occurrence of cardiovascular
symptoms observed in COVID-CS. In addition, increased VEGF and
decreased E-cadherin can lead to vascular permeability and
leakage and accelerate the presence of hypotension and
pulmonary dysfunction in COVID-CS.87 Moreover, IL-6 can
promote the secretion of various acute-phase proteins such as
CRP, hepcidin, fibrinogen, thrombopoietin, complement C3, and
ferritin in hepatocytes.118,119 Collectively, IL-6 contributes to both
immune cell hyperactivation and target organ dysfunction in CS.
Evidence has suggested that the production of IL-6 can be
induced by angiotensin II in inflamed vessels. The underlying
mechanism is that angiotensin II binds to angiotensin II type 1
(AT1) receptor and then activates JAK/STAT signaling to induce IL-
6 production.120,121 Interestingly, existing studies have shown that
SARS-CoV may promote the expression of angiotensin II by
downregulating ACE2,122,123 which potentially leads to the
possibility that SARS-CoV-2 enhances IL-6 production via the
angiotensin II/AT1 receptor/JAK/STAT axis, and the positive pro-
inflammatory feedback of IL-6/JAK/STAT ultimately drives clinical
signatures of COVID-19, especially COVID-CS.124
IFN-γ/JAK/STAT signaling. IFN-γ, mainly produced by macro-
phages, T cells, and NK cells, participates in immunological
processes such as inflammation. It is a dominating driver of
macrophage, NK, and T cell activation, and exerts a predominant
effect on protective immunity against bacterial and viral infections
through the activation of JAK1/JAK2 complex and downstream
STAT1-IFN-γ-activated site (GAS) cascades.125–127
Evidence has shown that IFN-γ is highly involved in various CS-
related disorders,128 as illustrated by its pathological role in
primary HLH, a syndrome of failure to eliminate pathogens owing
to impaired NK cell activity. In such cases, despite excessive T cell
activation and large quantities of IFN-γ production, the increased
IFN-γ levels fail to combat pathogens and instead cause
immunopathology because of defective NK activity.129 Whether
IFN-γ plays a specific role in COVID-CS is still unknown; however,
considering its role in promoting immune cell activation, we can
speculate that it contributes substantially to COVID-CS.
Numerous studies have reported elevated levels of IFN-γ in
patients with COVID-19.9,130,131 Of note, one study showed that
IFN-γ produced by CD4+ T cells was decreased in patients with
severe disease compared to those with moderate disease, which
could be explained by the reduced numbers and functional
exhaustion of T cells in severe COVID-19,132 as described– above.
Therefore, this study suggested that elevated levels of IFN-γ in
COVID-19 are produced mainly by macrophages, not T cells.
TNFα/NF-κB signaling. TNFα is a well-known pro-inflammatory
cytokine and is closely associated with many infectious, auto-
immune diseases, and cancer, and is primarily produced by
monocytes, macrophages, and T cells.133,134 NF-κB plays an
evolutionarily conserved role in the immune system,135,136
especially in regulating the expression of various vital cytokines
involved in inflammation.137 TNFα, as an initial driver of NF-κB
activation, can activate the NF-κB signaling pathway to induce the
expression of several pro-inflammatory and antiapoptotic genes
through its receptor TNFR1 and a series of intermediate
adapters.138–140 In turn, NF-κB can induce TNFα expression in
the context of inflammation, such as lipopolysaccharide (LPS)
stimulation.141 Therefore, TNFα/NF-κB signaling may play patho-
logical roles in the stage of initiation and immune cell
hyperactivation in CS by inducing apoptosis of epithelial cells to
drive the epithelium–immune cell interplay and augmenting
systemic inflammation.
Previous studies have found that excessive TNFα represented a
poor prognosis in SARS-CoV and MERS cases,142–145 and inhibition
of NF-κB improved pulmonary symptoms in SARS-CoV-infected
mice.146 However, the role of TNFα in COVID-19 is, so far, still not
entirely clear. Recent studies have reported elevated serum levels
of TNFα in severe COVID-19 cases.9,13,24,81 In addition, a clinical
trial from Wuhan, China, including 522 patients and 40 healthy
controls showed that the concentration of TNFα was negatively
correlated with T cell counts in COVID-19 patients.27 In contrast, a
clinical trial from Chongqing, China, including 102 mild and
21 severe cases showed that TNFα levels were within the normal
values in almost all COVID-19 patients (121/123).147 Thus, further
research is urgently required to better understand the role of TNFα
in COVID-CS. Although a recent report suggested that inhibition of
the TNFα–NF-κB pathway may have protective effects in COVID-
19,124 caution should be applied based on two aspects: (1) as
mentioned above, the roles of TNFα in COVID-CS is still undefined;
(2) blocking NF-κB nonspecifically may simultaneously impair its
protective functions in cellular homeostasis, as exemplified by a
general suppression on innate immunity.148
NLRP3/IL-1β signaling. IL-1β is perhaps the most well-studied
member of the IL-1 family because of its prominent role in
autoinflammatory diseases such as gout and chronic inflammatory
arthritis.149–151 IL-1β is mainly secreted by macrophages via
apoptosis and pyroptosis and exerts positive effects on the
migration of immune cells to inflamed tissues; Th17 cell
differentiation; expression and release of various cytokines and
adhesion factors; and NF-κB pathway activation to form a positive
feedback for its own production.152,153 Upstream, the NLRP3
protein forms a complex with apoptosis-associated speck-like
protein containing a caspase recruitment domain (ASC) and
cysteinyl aspartate-specific proteinase-1 (caspase-1), termed the
NLRP3 inflammasome, to cleave the inactive IL-1β precursor to the
mature form of IL-1β.154,155 Considering the positive roles of IL-1β
in activating initiative and sustained inflammation,156 it was
postulated that NLRP3-IL-1β signaling might be involved in
COVID-CS.
Multiple indicators from previous evidence have suggested that
IL-1β may contribute to CS in coronavirus infections.157–159 Zhang
et al.160 reported the elevated levels of multiple cytokines
including IL-1β in COVID-19 cases with severe symptoms, which
were also associated with SARS, hypercoagulation, and DIC.
Consistently, Huang et al.9 also showed high serum concentrations
of IL-1β in COVID-19 patients. Moreover, a previous study showed
that NLRP3 can be directly activated by viral proteins of SARS-CoV
such as ORF3a and ORF8b,161,162 which were also found on the
genome of SARS-CoV-2,163 suggesting a potentially similar effect
of direct activation of the NLRP3 by SARS-CoV-2 protein. The
potential roles of NLRP3 inflammasome in severe COVID-19 have
been discussed in relevant reviews.164,165 Reactive oxygen species
(ROS) was reportedly an initiator of NLRP3 activation.166–168 Thus,
it was proposed that excessive production of ROS resulting from
inflammation infiltration in severe COVID-19 may lead to NLRP3
activation and IL-1β precursor cleavage, further aggravating
inflammation in COVID-CS.
IL-2/IL-2R/JAK/STAT5 signaling. IL-2 is mainly secreted by CD4+
T cells and plays crucial roles in the expansion and differentiation
of CD4+ T, CD8+ T, NK, and other cells through the IL-
2R–JAK–STAT5 signaling pathway.169,170 IL-2 can fine-tune
immune responses and maintain self-tolerance,171 and its
deficiency accounts for the occurrence of autoimmune dis-
eases.172
Elevated levels of IL-2 have been reported in other types of
coronavirus infections.173,174 Recent studies have also shown that
the concentrations of IL-2 or IL-2R were elevated in COVID-19
patients, especially in those with severe illness.9,13,24,132 However,
a clinical trial including 54 COVID-19 patients from Beijing, China,
reported a contradictory result. The authors found that compared
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with severe patients (n= 14), those with a critical illness (n= 6)
had remarkably reduced plasma levels of IL-2. Accordingly, IL-2Rα
levels were significantly decreased in the PBMCs of patients with a
severe and critical illness compared to common patients (n= 34)
or healthy controls. Furthermore, the levels of JAK1 and STAT5
were significantly lower in all three groups than in normal
controls. Considering the supportive roles of IL-2 in the expansion
and differentiation of T cells, the authors speculated that the
presence of lymphopenia especially in severe COVID-19 may be
attributed to reduced levels of IL-2, IL-2R, JAK1, and STAT5.175 In
additionally, CD4+ T cells are the primary source of IL-2, and the
reduced numbers of lymphocytes during the stage of CS after
COVID-19 infection can at least partly explain the reduced IL-2
level and downregulation of IL-2 signaling. Future investigations
are required to confirm these findings in more patients.
IL-7/IL-7R signaling. IL-7/IL-7R signaling is essential for peripheral
homeostasis and the survival, differentiation, and maintenance of
T cells including CD4+ T, CD8+ T, naive T, and memory T cells.176–
179 It is also indispensable for the development and maintenance
of innate lymphoid cells (ILCs), formation of lymphoid structures,
and barrier defense.180
Recent reports have shown elevated levels of IL-7 in COVID-19
patients, and these increases were related to disease sever-
ity.9,13,147 However, the impact of enhanced levels of IL-7 in
COVID-19 is largely unknown. Considering the protective role of
IL-7, we can speculate that the increase of IL-7 may be a feedback
mechanism in response to the lymphopenia in patients with
severe/critical COVID-19.
IL-10 signaling. IL-10 is an important immunoregulatory cytokine
produced by a variety of immune cells including Th2 cells, Tregs,
CD8+ T cells, B cells, DCs, macrophages, and NK cells, and signals
through the IL-10R/JAK/STAT3 pathway. IL-10 exerts anti-
inflammatory functions by directly limiting the innate immune-
related functions of macrophages and DCs in an autocrine and
paracrine manner or indirectly via improving Treg development. In
addition, IL-10 can activate mast cells and strengthen the
functions of CD8+ T, B, and NK cells.181
A clinical trial including 102 COVID-19 patients and 45 controls
from Wuhan, China, showed that the serum IL-10 levels of patients
with a critical illness (n= 17) were significantly higher than those
of patients with moderate (n= 42) and severe (n= 43) illness;
further, the IL-10 levels were positively correlated with the
concentrations of serum CRP, indicating the potential of IL-10 as
an indicator of disease severity.182 Huang et al.9 also reported the
significantly high plasma levels of IL-10 in COVID-19 patients
admitted to the ICU compared to those who were not. In addition,
a follow-up clinical trial including 71 COVID-19 patients (53 mild
and 18 severe) from Beijing, China and 18 controls showed that
the production of IL-10 in the early stage was significantly
correlated with disease severity.183
It can be speculated that the excessive production of IL-10 is a
negative feedback mechanism to antagonize the hyperactivity of
the immune system. However, when faced with an overwhelming
secretion of inflammatory mediators and activation of pro-
inflammatory cells in COVID-CS, the fine-tune function of IL-10 is
rather inadequate. Thus, administration of IL-10 has been
recommended to treat ARDS in COVID-19.184 However, a recent
report showed that IL-10 may be detrimental in the initiation
phase of SARS-CoV-2 infection by promoting T cell exhaustion.
The authors proposed that blocking IL-10 with a neutralizing
antibody in the initiation stage of SARS-CoV-2 infection may be a
promising therapeutic approach.185
IL-12 signaling. IL-12, mainly produced by DCs, macrophages,
and B lymphocytes,186 is a multifunctional immunoregulatory
factor that can promote proliferation of Th1 and Th17 cells;
improve the cytotoxicity of NK cells; and induce expression of IFN-
γ in Th1 cells, NK cells, DCs, and macrophages via a positive
feedback mechanism.187,188 Thus, IL-12 plays an aggressive role in
CS by augmenting the activation of various immune cells.
Existing studies have reported that viral infections induce the
production of IL-12 to defend against infections.189–191 For
instance, during influenza virus infection, IL-12 is endogenously
produced to induce the secretion of IFN-γ from Th1 and NK cells,
thereby inhibiting viral replication.190 A previous study reported
elevated plasma levels of IL-12 in patients infected by SARS-
CoV.192 However, Huang et al.9 recently found that the plasma
levels of IL-12p70 showed no difference between COVID-19
patients and healthy adults. Therefore, further research with large-
sized samples is urgently required to determine the alterations
and functions of IL-12 in COVID-19, especially COVID-CS.
IL-17 signaling. IL-17 (primarily IL-17A) is produced by Th17,
CD8+ T, and group 3 ILC (ILC3) and participates in many pro-
inflammatory processes and autoimmune diseases.193–195 Target-
ing IL-17 is now regarded as a common strategy to reduce the
burden of several autoimmune diseases such as psoriasis and
psoriatic arthritis. Nevertheless, the functions of this inflammatory
cytokine vary, from being protective against infections to having
detrimental pro-inflammatory effects, depending on the tissue
type and location (gut, lung, or skin) where it is being expressed
and its triggering factors.196
Increased levels of IL-17 were previously reported in SARS-CoV-
or MERS-CoV-infected patients.197,198 In addition, IL-17 can
augment lung injury and decrease overall survival through
recruitment of neutrophils; stimulate the expression of pro-
inflammatory factors; and induce the expression of G-CSF to
prevent apoptosis in both ARDS and an LPS-induced acute lung
injury model.199,200 Similarly, evidence has suggested that IL-17
levels were elevated in COVID-19 patients, especially in those with
a severe and critical illness.201 Asrani and Hassan156 showed that
IL-17 plays crucial roles in the stages of immune cell hyperactiva-
tion and target organ dysfunction in COVID-CS by promoting the
recruitment of neutrophils and producing symptoms such as
fever, matrix damage, tissue remodeling, and inflammatory
infiltration.
Despite multiple evidence suggesting the potential of IL-17 as
an intervention target for COVID-CS, studies have shown that the
levels of IL-17 were within normal ranges in 102 and 21 patients
with mild and severe COVID-19, respectively.147 Therefore, more
clinical trials and fundamental research are required for further
clarification.
GM-CSF signaling. GM-CSF is produced by endothelial, epithelial,
hematopoietic, and other cell types.202 Under physiological
conditions, low levels of GM-CSF can regulate the homeostasis
of alveolar macrophages to maintain their antimicrobial func-
tions.203,204 Under hyperinflammatory conditions such as CS, GM-
CSF drives emergency myelopoiesis and recruits myeloid cells to
the inflammatory sites to perpetuate inflammatory reactions.205
Increased levels of GM-CSF have been observed in SARS,206
ARDS,207 and CRS.208 A recent study also reported elevated GM-
CSF levels in both severe and mild COVID-19.9
Given the role of GM-CSF in maintaining antimicrobial functions
of alveolar macrophages, administration of GM-CSF to patients
with early-stage COVID-19 may strengthen the alveolar wall and
enhance viral clearance.209 In contrast, the blockade of GM-CSF
signaling may achieve clinical benefits in COVID-CS.
CYTOKINE-BASED INTERVENTIONS
The current treatment for CS is mainly based on traditional anti-
inflammatory drugs such as the administration of corticosteroids,
chloroquine, and colchicines.210,211 Recently, biologics like
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recombinant cytokines; monoclonal antibodies against IL-6, IL-1β,
TNF-α, and IFN-γ; and signaling pathway inhibitors are also
available or in the pipeline for production. In this and the next
section, we aim to discuss the key biologics that are currently or
potentially applied to treat CS (Fig. 6).
IFN-I
Administration of IFN-I has previously been investigated for the
treatment of SARS-CoV and MERS-CoV. Generally, it was found to
be relatively effective in vitro and in some animal models,212
although human studies were inconclusive.213
The research team at the University of Texas Medical Branch,
USA, showed that low concentrations of IFN-α and IFN-β
effectively reduced virus titer and inhibited viral replication in
Vero cells in a dose-dependent manner, and they also found that
SARS-CoV-2 is more sensitive than SARS-CoV to IFN-I in vitro.214 An
uncontrolled, exploratory study from Tongji Medical College,
Wuhan, China, showed that administration of IFN-α2b alone or in
combination with arbidol remarkably accelerated virus clearance
as well as the recovery of IL-6 and CRP to normal levels in COVID-
19 patients.215 A randomized, multicenter, prospective, phase 2
clinical trial conducted at the University of Hong Kong showed
that compared with the control group (lopinavir/ritonavir), COVID-
19 patients in the triple group (IFNβ-1b plus lopinavir/ritonavir+
ribavirin) exhibited significantly alleviated symptoms; shortened
virus shedding and hospital stay; and improved inflammatory
conditions (NCT04276688).216 A prospective study including 2944
healthy medical staff in the epidemic areas from Taihe Hospital in
Shiyan City, Hubei, China, showed that the incidence rate of
COVID-19 was zero in both the low-risk group (n= 2415) and the
high-risk group (n= 529) after treatment with recombinant IFN-α
nose drops for 30 days (NCT04320238),217 indicating the
preventive roles of recombinant IFN-α in COVID-19. A trial
comparing the clinical efficacy of subcutaneous IFN-β1a plus
lopinavir/ritonavir with lopinavir/ritonavir alone; hydroxychloro-
quine; and remdesivir in COVID-19 is still ongoing (NCT04315948).
Collectively, these studies suggested that IFN-I can inhibit SARS-
CoV-2 infection and potential COVID-CS.
Another type of interferon—IFN-III—may also have a clinical
benefit in COVID-19 treatment. Dinnon et al.218 confirmed the
anti-viral effect of pegylated IFN-λ1a in both SARS-CoV-2-infected
human airway epithelial cells and mouse models. Some studies
have determined that MDA5 plays a leading role in activating IFN-
I/III response to defend against SARS-CoV-2 in human epithelial
cells,219–221 which may open a new avenue for enhancing IFN
response in COVID-19. In addition, several clinical trials evaluating
the clinical efficacy of IFN-λ are under investigation (NCT04343976,
NCT04331899).
IL-7
The supportive role of IL-7 in lymphocyte survival and expansion
provides clinical implications for the recovery of function of
lymphocytes in severe/critical COVID-19.
A case report from Hospices Civils de Lyon, France, showed that
a period of recombinant human IL-7 (rhIL-7) treatment remarkably
improved the immune function in a 74-year-old ICU patient with
severe COVID-19, which manifested as elevated lymphocyte count
and mHLA-DR expression. In this case, IL-7 was administered quite
late, on day 24 of admission. Thus, the authors prospectively
proposed that earlier administration of IL-7 may have indicated
better clinical outcomes.222 In a case series from St. Luc University
Hospital, Brussels, Belgium, the authors showed that patients in
the IL-7 treatment group seemed to have higher levels of
lymphocyte counts than those in the control group, without
aggravated inflammation and pulmonary injury.223 Unfortunately,
the absence of detailed phenotypic or functional studies on
lymphocytes weakens the reliability of these studies. A multi-
center, double-blind clinical trial in a UK-based cohort is currently
evaluating whether the administration of CYT107 (a commercial
product of rhIL-7) can result in clinical improvement of patients
with severe COVID-19 through immune reconstitution
(NCT04379076). Clark et al.224 proposed that administration of
Fig. 6 The potential inhibitors and therapies to counteract COVID-CS. A variety of inhibitors or drugs have been applied or are under
consideration to treat COVID-CS, including those targeting a single pro-inflammatory cytokine or its receptor and related signal pathway. In
addition, several treatments such as intravenous immunoglobulin, corticosteroids, traditional Chinese medicine, and CDK7 inhibitor may have
the potential to counteract multiple cytokines and pathways involved in COVID-CS. CDK7 cyclin-dependent kinase 7
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IL-7 in combination with dexamethasone may be an optimal
treatment for severe COVID-19. The underlying mechanism is that
dexamethasone enhances IL-7 activity by upregulating its receptor
IL‐7Rα, which can also be used to explain the most effective
properties of dexamethasone in the more severe stage of the
disease.225,226
These studies indicate that appropriate administration of IL-7
alone or in combination with other agents should be considered




As mentioned above, IL-6 signaling is a leading inducer of COVID-
CS. Currently, several drugs targeting IL-6 signaling such as IL-6
inhibitors (siltuximab, clazakizumab, sirukumab, olokizumab) and
IL-6R inhibitors (tocilizumab, sarilumab, levilimab) are avail-
able.227–229
A retrospective clinical trial from Anhui, China, including 21
COVID-19 patients with severe or critical illness showed that five
days of tocilizumab therapy immediately improved the clinical
outcomes in most patients, manifested as decreased oxygen
requirements, serum CRP concentrations, and hospital stays, as
well as the rapid recovery of lymphocyte percentage.230 Another
multicenter cohort study including 3924 COVID-19 patients in
the ICU across 68 hospitals in the United States showed that the
risk of mortality was lower in 433 patients who received
tocilizumab treatment immediately after ICU admission than in
those who did not receive early tocilizumab intervention.231 In
addition, numerous reports evaluating the administration of
tocilizumab for severe COVID-19 have also been pub-
lished,106,232–247 and a total of 75 clinical trials are currently
registered in ClinicalTrials. gov.
An open-label study from Italy including 56 patients with severe
COVID-19 showed that after 28 days of follow-up, sarilumab
treatment (n= 28) appeared to promote the recovery of patients
with mild lung consolidation (<17%) at baseline.248 Another
retrospective, single-center, clinical trial from Italy including 15
COVID-19 patients showed that sarilumab treatment improved the
clinical symptoms and reduced serum CRP levels in most patients
(n= 10).249 Currently, a total of 17 clinical trials on sarilumab are
registered in ClinicalTrials.gov for the treatment of COVID-19.
A randomized, phase 3, clinical trial evaluating the administra-
tion of levilimab in patients with severe COVID-19 has been
completed, but the results have not yet been published
(NCT04397562).
An observational, controlled cohort study from Italy including
30 patients requiring ventilator support showed that the 30-day
mortality was significantly reduced in those receiving siltuximab
plus optimal supportive care compared with the control patients
who received only optimal supportive care; ~50% of patients
receiving siltuximab treatment were finally discharged
(NCT04322188).250 Three other clinical trials evaluating the efficacy
and safety of siltuximab in severe COVID-19 are underway
(NCT04329650, NCT04330638, NCT04486521).
In general, published clinical trials showed positive results with
respect to some common IL-6 or IL-6R antagonists for the
treatment of COVID-CS. Several clinical trials of other IL-6 or IL-6R
antagonists including clazakizumab (NCT04381052, NCT04494724,
NCT04343989, NCT04363502, NCT04348500, NCT04659772); siru-
kumab (NCT04380961); and olokizumab (NCT04380519,
NCT04452474) have been registered in ClinicalTrials.gov to
investigate their therapeutic potential in COVID-CS.
Blockade of IL-1β
Considering the pathological role of IL-1β signaling in CS, several
drugs targeting IL-1β signaling, including IL-1β antagonist
canakinumab and IL-1 receptor antagonist anakinra, may offer
clinical benefits in the treatment of COVID-19, particularly in CS.
A retrospective, three-center, clinical trial from France including
22 patients with severe/critical COVID-19 showed that after
>8 days of treatment, patients in the anakinra group (n= 12)
presented improved clinical conditions as well as decreased
mechanical ventilation requirements and serum CRP concentra-
tions, as compared with the control group (n= 10) (INDS,
MR4115050520).251 A prospective, cohort study from the Nether-
lands showed that several clinical parameters including tempera-
ture; white blood cell count; and levels of plasma ferritin,
creatinine, procalcitonin, and bilirubin were decreased after
28 days of anakinra treatment.252 Several other studies have also
investigated the clinical effects of anakinra on COVID-19.253–261 A
total of 35 clinical trials are currently registered in ClinicalTrials.
gov.
A retrospective study from Italy reported for the first time that
subcutaneous administration of 300mg canakinumab rapidly
reduced systemic inflammation and improved oxygenation in
COVID-19 patients (n= 10) who presented hyperinflammation but
did not require mechanical ventilation.262 Another single-center,
cohort study from Italy enrolled 34 non-ICU patients with mild or
severe COVID-19, with 17 receiving standard treatment and 17
receiving 300 mg of subcutaneous canakinumab. The results
showed that canakinumab treatment significantly increased the
PaO2/FiO2 ratio and reduced inflammatory indices.
263 These two
studies suggest that canakinumab treatment may have therapeu-
tic potentials in non-ICU patients with mild or severe COVID-19.
Several other reports have also evaluated the administration of
canakinumab in COVID-19,264–266 and six clinical trials are
currently registered in ClinicalTrials.gov (NCT04348448,
NCT04476706, NCT04362813, NCT04365153, NCT04510493,
NCT04278404).
Blockade of IFN-γ
Emapalumab, a monoclonal antibody targeting IFN-γ, has been
approved to treat primary HLH, a condition with elevated serum
levels of IFN-γ.267 Considering the contribution of IFN-γ to CS as
mentioned above, emapalumab may be effective in the treatment
of COVID-CS.
A randomized, multicenter, clinical trial from Italy was registered
to investigate the efficacy of emapalumab treatment in combina-
tion with anakinra to alleviate hyperinflammation and improve
respiratory conditions (NCT04324021). Unfortunately, this trial is
now terminated and no further data are currently available.
Therefore, other randomized, controlled clinical trials are urgently
required to address these issues.
Blockade of TNFα
Recent studies have provided the theoretical and practical bases
to support TNFα blockade as a potential strategy for excessive
cytokine release and hyperinflammation in COVID-19.268–271
Etanercept is a soluble TNFα receptor fusion protein that has
been used to treat toxic epidermal necrolysis (TEN), a condition of
systemic hyperinflammation. Owing to the similarities in clinical
manifestations and pathological characteristics between COVID-19
and TEN, Chen et al.268 proposed the temporary use of etanercept
as a valuable approach to treat severe COVID-19. A case report
described that a 60-year-old man who received subcutaneous
etanercept treatment for spondyloarthritis prior to SARS-CoV-2
infection presented no signs of respiratory failure and progressive
deterioration and showed rapid recovery from COVID-19.269
Infliximab is another clinically approved TNFα blocker. A total of
four clinical trials of infliximab evaluating its therapeutic potential
in COVID-19 are currently underway (NCT04425538, NCT04734678,
NCT04593940, NCT04344249). Adalimumab is a monoclonal
antibody targeting TNFα and is currently undergoing evaluation
in two clinical trials (ChiCTR2000030089, NCT04705844).
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Despite these promising results, we cannot exclude the
possibility of chance, and hence, randomized, controlled, pro-
spective clinical trials with a large sample size are urgently
required for further validation.
Blockade of IL-12/IL-23
IL-12/23 inhibitors currently used in the clinic include risankizu-
mab, guselkumab, tildrakizumab (targeting IL-23p19), and usteki-
numab (targeting IL-12/IL-23p40) mainly for chronic inflammatory
and autoimmune diseases such as psoriasis and inflammatory
bowel disease.272–276 A recent review proposed IL-12/IL-23 or IL-23
inhibitors as potential interventional targets for the ongoing
COVID-19 pandemic.277
Several case reports have described the clinical efficacy of IL-12/
IL-23 inhibitors including ustekinumab, guselkumab, risankizumab,
and risankizumab in COVID-19 patients with psoriasis.278–282 The
reliability of case reports is relatively weak, which is why
randomized, controlled, prospective clinical trials are so important.
A multicenter, randomized, clinical trial is ongoing to evaluate
the efficacy of risankizumab alone or risankizumab in combination
with remdesivir in COVID-19 (NCT04583956).
Blockade of IL-17A
Several review articles have proposed targeting IL-17A signaling as
an intervening measure for patients with COVID-CS.196,283–289
Case reports from Italy have shown that patients with a history
of psoriasis and previous treatment with IL-17A antagonists
including secukinumab and ixekizumab showed relatively mild
COVID-19 symptoms or were even asymptomatic.290–292 A retro-
spective, observational, multicenter clinical trial from Italy contain-
ing 5206 patients with psoriasis who have been prescribed
medications including IL-17 inhibitors showed that only four
patients were hospitalized for COVID-19, and no deaths
occurred,293 indicating the protective role of IL-17A inhibitors in
COVID-CS and ARDS. However, using the general Italian popula-
tion as the control group reduces the degree of standardization
and reliability of this trial. The absence of standard clinical or
experimental diagnosis for COVID-19 is another limitation. In
addition, other prospective, randomized, clinical trials evaluating
the administration of ixekizumab (NCT04724629) and secukinu-
mab (NCT04403243) in COVID-19 are also underway. In addition,
many researchers have proposed that simultaneously targeting IL-
17A signaling and synergic IL-6 signaling may offer more clinical
benefit for COVID-19 patients, particularly for those who
experience CS.283,286
Blockade of GM-CSF
Several studies have reported the protective roles of GM-CSF in
the early stage of infection,294–296 and numerous clinical trials of
human recombinant GM-CSF including sargramostim and mol-
gramostim have been registered for the treatment of COVID-19;
however, as mentioned above, GM-CSF indeed exerts a patholo-
gical function in the phase of CS, implying that blocking GM-CSF
signaling may achieve clinical benefits in COVID-CS.
Mavrilimumab is a monoclonal antibody against GM-CSF-Rα.297
A prospective cohort study from Italy including 39 patients with
severe COVID-19 showed that patients in the mavrilimumab group
(n= 13) showed earlier improvement, lesser progression to
mechanical ventilation, and faster fever resolution than those in
the control group (n= 26).298 In addition, several clinical trials
evaluating the administration of mavrilimumab in severe COVID-
19 have been registered (NCT04447469, NCT04463004,
NCT04492514, NCT04399980, NCT04397497).
Lenzilumab is a recombinant monoclonal antibody against
human GM-CSF. A case–cohort study including 39 patients with
severe COVID-19 from the USA reported that compared to the
control group (n= 27), patients who received intravenous
treatment with lenzilumab (n= 12) exhibited significantly rapid
clinical improvement; reduced progression to ARDS; and
decreased inflammatory markers and inflammatory myeloid
cells.299 In addition, several clinical trials for lenzilumab have
been registered for the treatment of severe COVID-19
(NCT04351152, NCT04583969, NCT04534725).
These clinical trials showed that blockade of GM-CSF signaling
indeed improved clinical outcomes in patients with COVID-CS.
Moreover, several other GM-CSF inhibitors such as gimsilumab,
otilimab, and TJ003234 are undergoing clinical evaluation as
potential COVID-19 therapy (NCT04351243, NCT04376684,
NCT04341116, respectively).
BLOCKADE OF SIGNALING PATHWAYS
Blockade of JAK/STAT signaling
The JAK/STAT pathway lies downstream of various cytokines
involved in the CS. Thus, several studies have proposed that the
JAK/STAT signaling inhibition may be a valuable preventive or
therapeutic option for COVID-CS.126,300–305 The clinical efficacy of
various JAK inhibitors (JAKinibs) such as tofacitinib targeting JAK1
and JAK3306,307 as well as baricitinib and ruxolitinib, both targeting
JAK1 and JAK2,308–310 are currently under investigation in clinical
trials in the context of COVID-19.
Hoang et al.311 found that baricitinib treatment significantly
improved the inflammatory condition in SARS-CoV-2-infected
rhesus macaque, as manifested by reduced inflammatory cell
infiltration and neutrophil recruitment; limited lung pathology;
and suppressed expression of pro-inflammatory mediators in lung
macrophages. Baricitinib has also been evaluated in a series of
clinical trials. An observational, longitudinal trial including 76
COVID-19 patients showed that compared with the control group
(n= 56), patients in the baricitinib group (n= 20) presented
remarkably reduced serum levels of IL-6, IL-1β, and TNF-α;
accelerated recovery of blood T and B cell counts; increased
production of antibodies against SARS-CoV-2; and progressively
increased PaO2/FiO2 ratio (NCT04438629).
109 Another observa-
tional cohort study from Spain showed that baricitinib improved
lung function in patients with moderate-to-severe COVID-19
receiving corticosteroid treatment.312 Interestingly, existing stu-
dies showed that besides the acknowledged inhibitory effects on
CS, baricitinib can also dampen ACE2-mediated SARS-CoV-2
endocytosis by inhibiting AP2-associated protein kinase 1 and
cyclin G-associated kinase,313,314 which serves as another mechan-
ism of its action in COVID-19. Moreover, several other reports have
also been published,313,315–322 and numerous clinical trials of
baricitinib are registered at ClinicalTrials.gov to evaluate its clinical
effects in severe COVID-19.
Several studies have shown that ruxolitinib may also be
effective in the treatment of severe/critical COVID-19.323–326 In a
prospective, multicenter, single-blind, phase 2 clinical trial
including 41 COVID-19 patients from Wuhan, China, compared
with patients in the placebo group (n= 21), those in the
ruxolitinib group (n= 20) exhibited remarkably reduced levels of
seven cytokines, as well as a faster rate of clinical improvement
and lymphocyte-count recovery.325 In addition, several other
clinical trials for ruxolitinib evaluation and six clinical trials that are
evaluating the administration of tofacitinib in COVID-19 patients
have been registered at ClinicalTrial.gov (NCT04412252,
NCT04415151, NCT04750317, NCT04469114, NCT04390061,
NCT04332042).
Despite these promising clinical data, JAKinibs should be used
with caution because of their side effects, based on the following
considerations: (1) nonselective inhibition of the JAK/STAT path-
way increases the risk of secondary infection such as herpes zoster
virus reactivation given its general inhibitory effects on multiple
aspects of physiological actions, including the innate immune
system.327,328 In addition, considering the general immunosup-
pressive nature, some researchers are concerned that continuous
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treatment with JAKinibs for autoimmune diseases may increase
the risk of SARS-CoV-2 infections or contribute to poor outcomes
in COVID-19. Hence, several retrospective clinical trials have been
conducted to address these concerns;329–334 (2) critical COVID-19
is commonly accompanied by coagulopathy and thrombosis, and
the Food and Drug Administration has warned that administration
of some JAKinibs has increased the risk of thrombosis.335 Thus,
developing JAKinibs with better specificity could be a future
direction of research aimed to prevent/reduce CS and improve the
survival of COVID-19 patients.
Blockade of NF-κB signaling
The overwhelming expression of multiple pro-inflammatory
proteins in COVID-CS has indicated the central roles of pro-
inflammatory signaling pathways, and in particular, the NF-κB
pathway. Immunomodulation of NF-κB activation has been
proven effective in SARS-CoV-infected cells or mice.146 Thus,
recent reviews have proposed that the NF-κB pathway represents
a potential therapeutic target for critical COVID-19 illness.336–338
An in vitro study showed that phillyrin (KD-1), a well-studied
anti-inflammatory and antioxidative agent, significantly reduced
the replication of SARS-CoV-2 and expression of pro-inflammatory
factors in Huh-7 cells via inhibition of the NF-κB signaling
pathway.339 Another study showed that a novel pyrazole
derivative remarkably reduced the expression of IL-6, TNFα, and
IL-1β in LPS-stimulated RAW267.4 cells by inhibiting NF-κB
signaling pathway activation.340 It has been suggested that
blocking phosphorylation of the inhibitor of NF-κB kinase subunit
beta, a primary downstream protein of NF-κB signaling, with
pharmacological inhibitors may be an effective approach for
COVID-CS treatment.339 Moreover, Liu Shen capsules, a traditional
Chinese medicine, were also reported to exert anti-viral and anti-
inflammatory effects in SARS-CoV-2-infected Huh-7 and Vero E6
cells, respectively, by suppressing the NF-κB signaling cascade.341
The effect of several anti-inflammatory or anti-viral drugs on
COVID-19 such as dexamethasone,342 hydroxychloroquine,343
macrolide antibiotics,344,345 and N-acetylcysteine346,347 are also
related to NF-κB cascade inhibition.
Despite the existence of various nonselective agents for NF-κB
inhibition, developing selective NF-κB inhibitors and a series of
clinical trials are urgently required to further validate the clinical
benefits.
Blockade of NLRP3 signaling
Several studies have shown that NLRP3 inflammasome is a
potential therapeutic target for COVID-CS.164,348,349
NLRP3 signaling inhibition may be a potential mechanism of
action for several anti-inflammatory drugs effective in COVID-19,
such as colchicine. Studies have shown that colchicine can
nonselectively inhibit NLRP3 inflammation by inhibiting the activa-
tion of P2X7 receptor or the interaction between NLRP3 protein and
ASC.350,351 In addition, chloroquine352 and curcumin353 are also
capable of inhibiting NLRP3 signaling. Several investigational agents
capable of inhibiting NLRP3 activation, such as tranilast,354
dapansutrile (OLT1177, selective inhibitor),354 and thiazolo-alkenyl
sulfonylurea derivative 7,355 are also being considered for COVID-CS
treatment as reviewed by Freeman and Swartz.164 In addition, some
nonselective or selective agents against NLRP3 inflammasome
including melatonin (NCT04409522), OLT1177 (NCT04540120), açai
palm berry extract (Euterpe oleracea) (NCT04404218), and ZYIL1
(selective inhibitor) (NCT04731324) are under investigation.
INTERVENTIONS TARGETING MULTIPLE CYTOKINES AND
PATHWAYS
Intravenous immunoglobulin (IVIg) therapy
IVIg is a natural immunoglobulin pool with a highly diverse
antibody network and is administered to superimpose over a
patient’s imbalanced repertoire caused by infections.356 It has
been known for a while that a broad range of natural anti-cytokine
autoantibodies such as those against IL-1, IL-6, and IFN-γ can be
detected in the IVIg of healthy individuals.357–360 Although how
the autoantibodies are induced is still poorly understood, it has
been demonstrated that many of the anti-cytokine autoantibodies
are neutralizing antibodies and may be responsible for the anti-
inflammatory effect of IVIg in inflammatory and autoimmune
disorders.
The potential efficacy of IVIg therapy was reported in SARS
and the 2009 H1N1 influenza pandemic.361,362 In a randomized,
controlled trial including 84 COVID-19 patients, IVIg treatment
did not demonstrate any therapeutic benefits in severe cases;
however, a significant positive relationship between the number
of days from admission to IVIg treatment and the length of
hospitalization was observed,363 which indicated the potential
clinical benefit of IVIg administration during the early stage of
COVID-19. In contrast, Suzuki et al.364 reported the potential
efficacy of IVIg administration along with mechanical ventilation,
methylprednisolone, favipiravir, ivermectin, and tocilizumab
therapy in the late phase in an elderly patient with severe
COVID-19.
In general, these studies were inconsistent with respect to the
timing of IVIg administration, i.e., early phase vs. late phase;
therefore, a larger number of clinical trials are warranted.
Corticosteroid treatment
Corticosteroids are one of the most commonly used anti-
inflammatory drugs in the treatment of many inflammatory
disorders. They exert immunoregulatory effects by inhibiting the
expression of multiple pro-inflammatory cytokines and activation of
various immune cells. At the beginning of 2020, corticosteroid
treatment in COVID-19 was either contraindicated or not recom-
mended,365 because of the statement that no clinical data indicated
a benefit from corticosteroid treatment. Moreover, it even increased
the mortality and secondary infection rates in SARS-CoV and MERS-
CoV.366 In March 2020, the RECOVERY trials, one of the largest
randomized, controlled trials for COVID-19 treatments including
~15% of all hospitalized COVID-19 patients in the UK, were launched.
The dexamethasone arm enrolled 2104 patients receiving a low-to-
moderate dexamethasone dose of 6mg per day for 10 days and the
control arm comprised 4321 patients receiving standard care.
Compared to the control group, dexamethasone treatment reduced
the 28-day mortality by one-third in mechanically ventilated patients
and by one-fifth in patients receiving oxygen only, but not in patients
with no need for ventilated support.367 Therefore, the UK govern-
ment (https://www.gov.uk/government/news/world-first-coronaviru
s-treatment-approved-for-nhs-use-by-government/) and the National
Institutes of Health in the United States (https://www.covid19treat
mentguidelines.nih.gov/dexamethasone/) have authorized the stan-
dard use of dexamethasone in hospitalized COVID-19 patients who
require oxygen. In addition, a meta-analysis of seven clinical trials
showed that corticosteroid treatment was associated with a lower
28-day all-cause mortality in critically ill COVID-19 patients.225
Collectively, the clinical benefit of glucocorticoids in COVID-19
treatment is based on the selection of the correct dose, correct
patient, and appropriate timing. Several studies have shown the
temporal dynamics of viral shedding in SARS-CoV-2.368–370 After
the replicative peaks, immunopathological factors may play a
dominant role in the illness, while active viral replication may play
a secondary one. Therefore, the viral load may serve as an
indicator to determine the precise time of glucocorticoid
treatment. Moreover, in contrast to other agents, dexamethasone
is readily available worldwide at a low cost, which is beneficial in
developing countries with limited access to health care. However,
although corticosteroid improves clinical syndromes in critically ill
COVID-19 patients, its impact on CS is still unclear and requires
further investigation.
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Traditional Chinese medicine (TCM) treatment
Previous studies have reported the therapeutic effects of several
TCMs such as Lizhong Decoction,371 Liujunzi Decoction,372 and
Huanglian Jiedu Decoction373 on inflammatory diseases. Recently,
TCM treatment has also been shown effective for COVID-19 and
contributed substantially to control the pandemic in China. For
example, a multicenter, randomized, controlled trial by Nanshan
Zhong’ research team showed that Lianhuaqingwen capsule, a
repurposed Chinese herb, can ameliorate clinical symptoms and
shorten the recovery time in COVID-19 patients with no serious
adverse effects.374
Several TCMs may play an immunosuppressive role to treat CS via
multiple cytokines or pathways related to the CS. Yang et al.375
showed that Qingfei Paidu Decoction, one of the most well-known
anti-COVID-19 formulae, can defend against COVID-19 by regulating
multiple CS-related signaling pathways such as the NF-κB and MAPK
pathways and cytokines such as TNF-α, IL-1β, and IL-8. In addition,
Dai et al.376 conducted a large-scale transcriptional study to evaluate
the effects of 578 herbs and all 338 reported anti-COVID-19 TCM
formulae on CS-related signaling, by combining high-throughput
sequencing-based screening assay with bioinformatics and
computer-aided drug design. The results showed that some herbs
might inhibit the IL-6 pathway, some, the TNF-α pathway, and some
drugs such as Guizhi and Qingfei Paidu Decoction may inhibit both
pathways. Together, these studies provide scientific evidence for the
administration of TCMs in COVID-CS.
Blockade of cyclin-dependent kinase 7 (CDK7)
It is challenging to block individual cytokines to achieve the desired
clinical benefit given the complicated crosstalk of cytokine signaling
during CS.377 Thus, developing anti-inflammatory strategies with a
wide-spectrum inhibitory effect is urgently required.
CDK7 can regulate cell cycle and gene transcription.378 Previous
studies have shown that blockade of CDK7 manipulated
inflammation resolution by remodeling antitumor immunity378
and regulating cytokine secretion.379 A recent study by Wei
et al.380 showed that small-molecule inhibitor, THZ1, mediated the
blockade of CDK7 and thus mitigated hyperinflammatory states
and CRS caused by CAR T cell therapy. Mechanistically, when CDK7
is blocked by THZ1, various pro-inflammatory genes, especially
STAT1 and IL1 that are regulated by CDK7/RNA Pol II super-
enhancers, are preferentially suppressed at the transcriptional
level. This indicates that blockade of CDK7 may be a promising
strategy to treat CRS. Considering similar cytokine profiles
between COVID-CS and CRS, we can hypothesize that the strategy
may also work in COVID-CS.
CONCLUSIONS
Clinical and basic research studies have identified and character-
ized COVID-CS, which has greatly enhanced our understanding of
CS and related immunopathology in COVID-19. A full scenario of
COVID-CS is now emerging, and it appears to be much larger in
scale and contains more cytokines than the CS recognized in other
conditions, and is therefore also more damaging. Although it is
still unclear how the virus turns the protective cytokine profile into
an inflammatory CS, the cytokines appear to be produced
predominantly by innate cells because the lymphopenia was
frequently reported in this condition. While the causative efficacy
of individual cytokines on the development of certain immuno-
pathogenic parameters in this condition is yet to be fully
understood; it is obvious that COVID-CS as a whole is closely
associated with the major pathogenic changes of COVID-19. To
treat COVID-CS, several biologic interventions specifically target-
ing inflammatory cytokines or related signaling pathways have
been clinically evaluated with promising results and many others
are in the pipeline.
In principle, the treatment strategy should be to control
ongoing inflammatory cytokine production or activity and resume
the host’s homeostasis. However, we still lack safe and effective
drugs to control the CS, and clinically, the treatment of CS has
been proved difficult for several reasons: (1) many medical doctors
are not aware of the condition and hence, clinical diagnosis and
treatment guidelines are currently lacking; (2) it is a pharmaceu-
tical challenge to simultaneously target multiple cytokines. It is
therefore important to identify and target the key cytokines
upstream and the cytokine induction network, or directly target
the predominant cytokine-producing cells such as monocytes and
macrophages. Alternatively, learning from the host immunoregu-
latory system and identifying more effective and safer anti-
inflammatory factor/cytokines with a wide-spectrum inhibitory
effect may provide a better option for therapeutic intervention; IL-
37 has been suggested for this purpose;381–384 (3) it is difficult to
balance CS and protective immunity in infectious diseases, as the
appropriate level of inflammatory cytokines is protective against
infections and inappropriately targeting inflammatory cytokines
may lead to acquired immunodeficiency and subsequent infec-
tions; (4) differences among individuals with respect to age,
immune status, and other comorbidities may result in virtual
differences in the component and scale of the CS and treatment.
Therefore, precise treatment is required. Of note, ideally targeting
predominant cytokines or molecular pathways in a particular CS
condition should be conducted first and in a timely manner.
COVID-19 has taught us a critical lesson regarding how to deal
with natural pathogenic enemies. Knowledge and treatment
options developed from COVID-CS will be invaluable, not just for
this disease but also for other CS conditions.
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